Evidence map›Paper›PMID 31382583›Full record

ArticleJournal of clinical medicine2019

Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk-A Single Center Experience.

Hannes Neuwirt, Irmgard Leitner-Lechner, Julia Kerschbaum, Michael Ertl, Florian Pöggsteiner, Nicolas Pölt, Julius Mätzler, Hannelore Sprenger-Mähr, Michael Rudnicki, Peter Schratzberger and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. The Role of Belatacept-Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation.Transplant infectious disease : an official journal of the Transplantation Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Hannes NeuwirtDepartment of Internal Medicine IV-Nephrology and Hypertension, Medical University of Innsbruck, Anichstrasse 35, Innsbruck A-6020, Austria. Hannes.Neuwirt@i-med.ac.at.ORCID 0000-0003-1064-0098
Irmgard Leitner-LechnerDepartment of Pharmacology, Section for Molecular and Cellular Pharmacology, Medical University of Innsbruck, Peter-Mayr-Strasse 1a, Innsbruck 6020, Austria.
Julia KerschbaumDepartment of Internal Medicine IV-Nephrology and Hypertension, Medical University of Innsbruck, Anichstrasse 35, Innsbruck A-6020, Austria.
Michael ErtlDepartment of Internal Medicine IV-Nephrology and Hypertension, Medical University of Innsbruck, Anichstrasse 35, Innsbruck A-6020, Austria.
Florian PöggsteinerDepartment of Internal Medicine IV-Nephrology and Hypertension, Medical University of Innsbruck, Anichstrasse 35, Innsbruck A-6020, Austria.
Nicolas PöltDepartment of Internal Medicine IV-Nephrology and Hypertension, Medical University of Innsbruck, Anichstrasse 35, Innsbruck A-6020, Austria.
Julius MätzlerDepartment of Internal Medicine IV-Nephrology and Hypertension, Medical University of Innsbruck, Anichstrasse 35, Innsbruck A-6020, Austria.
Hannelore Sprenger-MährLandeskrankenhaus Feldkirch, Department of Internal Medicine III-Nephrology, Carinagasse 47, Feldkirch 6800, Austria.
Michael RudnickiDepartment of Internal Medicine IV-Nephrology and Hypertension, Medical University of Innsbruck, Anichstrasse 35, Innsbruck A-6020, Austria.
Peter SchratzbergerDepartment of Internal Medicine IV-Nephrology and Hypertension, Medical University of Innsbruck, Anichstrasse 35, Innsbruck A-6020, Austria.
Iris E EderDepartment of Urology, Medical University of Innsbruck, Anichstrasse 35, Innsbruck A-6020, Austria.
Gert MayerDepartment of Internal Medicine IV-Nephrology and Hypertension, Medical University of Innsbruck, Anichstrasse 35, Innsbruck A-6020, Austria.
Innsbruck Medical University · ATLandeskrankenhaus Feldkirch · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Belatacept is an attractive option for immunosuppression after renal transplantation. Renal allograft function is superior when compared to calcineurin inhibitor (CNI) based therapy in "de novo" treated patients and it has also been proposed that individuals at high cardiovascular (CV) risk may benefit most. In this retrospective cohort study, we assessed the efficacy and safety of treating patients at high cardiovascular risk with Belatacept (

Indexed as

Belataceptcardiovascular high riskkidney transplantationoutcome

Identifiers

PMID31382583
PMCPMC6723198
OpenAlexW2966406558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.